Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lushang Freda Pharmaceutical CoSHSE:600223 68 Pretax Margin % is 4.87% as of Mar. 2026, which is 9% below its 10-year median of 5.37. GuruFocus rates SHSE:600223 with a GF Score™ of 68/100 and a GF Value™ of ¥6.56 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,756 Real Estate companies, Lushang Freda Pharmaceutical Co ranks worse than 58.54% on this metric.
Lushang Freda Pharmaceutical Co (SHSE:600223) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Lushang Freda Pharmaceutical Co Pretax Margin % Related Terms
Lushang Freda Pharmaceutical Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lushang Freda Pharmaceutical Co Pretax Margin % Chart
Lushang Freda Pharmaceutical Co Pretax Margin % Competitor Comparison
For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lushang Freda Pharmaceutical Co Pretax Margin % vs Real Estate Industry
For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Lushang Freda Pharmaceutical Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lushang Freda Pharmaceutical Co (SHSE:600223) has a Pretax Margin % of 4.87% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Lushang Freda Pharmaceutical Co and its competitors. This is near median its historical median of 5.37. Over the past decade, Lushang Freda Pharmaceutical Co's Pretax Margin % has ranged from 2.02 to 9.02. According to the industry distribution chart, Lushang Freda Pharmaceutical Co ranks #1028 out of 1756 companies in the Real Estate industry, placing it in the top 58.5%.
Is Lushang Freda Pharmaceutical Co's Pretax Margin % too high?
Lushang Freda Pharmaceutical Co's current Pretax Margin % of 4.87% is near median its 10-year median of 5.37. Over the past 10 years, this metric has ranged from a low of 2.02 to a high of 9.02. The Real Estate industry median Pretax Margin % is 12.22. Lushang Freda Pharmaceutical Co's value of 4.87% is 60.1% below this industry median. Based on the distribution chart, Lushang Freda Pharmaceutical Co ranks #1028 out of 1756 companies in the Real Estate industry, which is below the industry midpoint. Overall, Lushang Freda Pharmaceutical Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lushang Freda Pharmaceutical Co's Pretax Margin % compare to competitors?
According to the Real Estate industry distribution chart, Lushang Freda Pharmaceutical Co ranks #1028 out of 1756 companies for Pretax Margin %. This places Lushang Freda Pharmaceutical Co in the lower half of its industry. The industry median Pretax Margin % is 12.22. Lushang Freda Pharmaceutical Co's value of 4.87% is 60.1% below this benchmark. Historically, Lushang Freda Pharmaceutical Co's own Pretax Margin % has ranged from 2.02 to 9.02 over the past decade. While the company's 10-year median is 5.37 vs. the industry median of 12.22, Lushang Freda Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Real Estate company?
The median Pretax Margin % among Real Estate companies is 12.22, based on 1,756 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lushang Freda Pharmaceutical Co's current Pretax Margin % of 4.87% is 60.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Lushang Freda Pharmaceutical Co and its competitors. For the Real Estate industry, the median Pretax Margin % is 12.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lushang Freda Pharmaceutical Co's current Pretax Margin % is 4.87%, which is near median its own 10-year median of 5.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lushang Freda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co (SHSE:600223) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥6.56, compared to a current price of ¥5.49 — trading 16.3% below its estimated fair value. The current Pretax Margin % is 4.87%, which is near median its 10-year median of 5.37 and 60.1% below the Real Estate industry median of 12.22. Lushang Freda Pharmaceutical Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Lushang Freda Pharmaceutical Co (SHSE:600223), the current Pretax Margin % is 4.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lushang Freda Pharmaceutical Co (SHSE:600223) Overvalued in 2026?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥5.49 is trading 16.3% below its estimated GF Value™ of ¥6.56.
GuruFocus considers Lushang Freda Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600223:
Pretax Margin %: 4.87% (near median its 10-year median of 5.37)
GF Value™: ¥6.56 vs. price of ¥5.49 (16.3% below fair value)
Industry Position: 60.1% below the Real Estate median (#1028 of 1756)
No single metric tells the full story. See the SHSE:600223 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
68GF Score
Get the complete analysis for SHSE:600223
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600223 has been successfully added to your 
